Financial performance of Varian Medical Systems
In 1Q18, Varian Medical Systems (VAR) reported revenues of $679 million, which is a YoY (year-over-year) rise of 13% on a reported basis and an 11% rise on a constant currency basis. It was mainly driven by increased sales of its linac (linear accelerator) systems in the oncology operating segment. The company’s product sales were $366 million, which is an 18% YoY growth. Services accounted for the remaining $313 million of revenues in 1Q18, which was a YoY rise of 7%.
In 1Q18, the company’s oncology operating segment reported revenues of $649 million, which is a YoY rise of 14%. The particle therapy operating segment reported revenues of $29 million, which is a 4% decline on a YoY basis.
In 1Q18, Varian Medical Systems reported gross orders worth $666 million, which is a YoY rise of 15%. Orders for products in the oncology segment rose YoY by 7%, while there were two new proton device orders in 1Q18. Varian continues to be a leading player in the global radiation therapy market, which is estimated to have grown 4.5% based on total orders since January 2017.
Analyst recommendations for Varian Medical Systems
Of the eight analysts covering Varian Medical Systems in March 2018, three have recommended a “strong buy,” three have recommended a “hold,” and two have recommended a “sell.”
Analyst recommendations for peers
Of the 17 analysts covering Baxter International (BAX) in March 2018, 50.9% have recommended a “buy.” About 80.0% of the 25 analysts covering Boston Scientific (BSX) stock have recommended a “buy,” and 80.9% of the 21 analysts tracking Abbott Laboratories (ABT) have recommended a “buy.”
In the next part of this series, we’ll look at Varian Medical Systems’ revenue growth prospects.